Insilico-accelerated drug discovery aside, one clinically oriented delivery theme that emerged in the dataset is long-term intranasal oxytocin work aimed at stabilizing exposure beyond short-lived dosing schedules. The coverage describes efforts toward achieving sustained hormone delivery intranasally with a focus on maintaining pharmacologic activity over time. While details on specific indications and clinical outcomes were limited, the approach aligns with broader interest in noninvasive administration routes to improve adherence and reduce dosing friction. The next checkpoint for this line is whether longer-lasting intranasal formulations translate to measurable effects in controlled clinical settings for targeted neurologic and psychosocial outcomes.